203 related articles for article (PubMed ID: 36697001)
1. Cancer immunotherapy and the management of side effects.
Mahalingam P; Newsom-Davis T
Clin Med (Lond); 2023 Jan; 23(1):56-60. PubMed ID: 36697001
[TBL] [Abstract][Full Text] [Related]
2. The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registry.
Ruste V; Goldschmidt V; Laparra A; Messayke S; Danlos FX; Romano-Martin P; Champiat S; Voisin AL; Baldini C; Massard C; Laghouati S; Marabelle A; Lambotte O; Michot JM
Eur J Cancer; 2021 Nov; 158():217-224. PubMed ID: 34627664
[TBL] [Abstract][Full Text] [Related]
3. A Review of Cancer Immunotherapy Toxicity: Immune Checkpoint Inhibitors.
Chhabra N; Kennedy J
J Med Toxicol; 2021 Oct; 17(4):411-424. PubMed ID: 33826117
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy Toxicities.
Sanchez K; Page DB; Urba W
Surg Oncol Clin N Am; 2019 Jul; 28(3):387-401. PubMed ID: 31079795
[TBL] [Abstract][Full Text] [Related]
5. Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune checkpoint inhibitor endocrinopathies and the role of advanced practice providers in the management of immune-mediated toxicities.
Cooksley T; Girotra M; Ginex P; Gordon RA; Anderson R; Blidner A; Choi J; Dougan M; Glezerman I; Gupta D; Johnson D; Shannon VR; Suarez-Almazor M; Rapoport BL
Support Care Cancer; 2020 Dec; 28(12):6175-6181. PubMed ID: 32856213
[TBL] [Abstract][Full Text] [Related]
6. Checkpoint Inhibitors: Common Immune-Related Adverse Events and Their Management
.
Gordon R; Kasler MK; Stasi K; Shames Y; Errante M; Ciccolini K; Skripnik Lucas A; Raasch P; Fischer-Cartlidge E
Clin J Oncol Nurs; 2017 Apr; 21(2 Suppl):45-52. PubMed ID: 28315555
[TBL] [Abstract][Full Text] [Related]
7. Management of Immune Checkpoint Inhibitor Toxicities: A Review and Clinical Guideline for Emergency Physicians.
Hryniewicki AT; Wang C; Shatsky RA; Coyne CJ
J Emerg Med; 2018 Oct; 55(4):489-502. PubMed ID: 30120013
[TBL] [Abstract][Full Text] [Related]
8. Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-mediated cardiovascular, rheumatic, and renal toxicities from checkpoint inhibitors.
Suarez-Almazor ME; Pundole X; Abdel-Wahab N; Johnson DB; Gupta D; Glezerman I; Cooksley T; Anderson R; Blidner A; Choi J; Dougan M; Ginex P; Girotra M; Shannon VR; Rapoport BL
Support Care Cancer; 2020 Dec; 28(12):6159-6173. PubMed ID: 32856212
[TBL] [Abstract][Full Text] [Related]
9. Acute and Long-term Adverse Events Associated With Checkpoint Blockade.
Davies M
Semin Oncol Nurs; 2019 Oct; 35(5):150926. PubMed ID: 31514992
[TBL] [Abstract][Full Text] [Related]
10. Patterns of toxicity burden for FDA-approved immune checkpoint inhibitors in the United States.
Yang F; Shay C; Abousaud M; Tang C; Li Y; Qin Z; Saba NF; Teng Y
J Exp Clin Cancer Res; 2023 Jan; 42(1):4. PubMed ID: 36600271
[TBL] [Abstract][Full Text] [Related]
11. A review of cancer immunotherapy toxicity.
Kennedy LB; Salama AKS
CA Cancer J Clin; 2020 Mar; 70(2):86-104. PubMed ID: 31944278
[TBL] [Abstract][Full Text] [Related]
12. Critical Care Management of Toxicities Associated With Targeted Agents and Immunotherapies for Cancer.
Gutierrez C; McEvoy C; Munshi L; Stephens RS; Detsky ME; Nates JL; Pastores SM
Crit Care Med; 2020 Jan; 48(1):10-21. PubMed ID: 31725440
[TBL] [Abstract][Full Text] [Related]
13. From a Patient Advocate's Perspective: Does Cancer Immunotherapy Represent a Paradigm Shift?
Madden DL
Curr Oncol Rep; 2018 Feb; 20(1):8. PubMed ID: 29411148
[TBL] [Abstract][Full Text] [Related]
14. Management of Immunotherapy-Related Toxicities in Patients Treated With Immune Checkpoint Inhibitor Therapy.
Reid PD; Cifu AS; Bass AR
JAMA; 2021 Feb; 325(5):482-483. PubMed ID: 33528524
[No Abstract] [Full Text] [Related]
15. Achilles' Heel of currently approved immune checkpoint inhibitors: immune related adverse events.
Yan T; Yu L; Zhang J; Chen Y; Fu Y; Tang J; Liao D
Front Immunol; 2024; 15():1292122. PubMed ID: 38410506
[TBL] [Abstract][Full Text] [Related]
16. T-cell-based Immunotherapies for Haematological Cancers, Part A: A SWOT Analysis of Immune Checkpoint Inhibitors (ICIs) and Bispecific T-Cell Engagers (BiTEs).
Rallis KS; Hillyar CRT; Sideris M; Davies JK
Anticancer Res; 2021 Mar; 41(3):1123-1141. PubMed ID: 33788704
[TBL] [Abstract][Full Text] [Related]
17. Immune mechanisms of toxicity from checkpoint inhibitors.
Wang SJ; Dougan SK; Dougan M
Trends Cancer; 2023 Jul; 9(7):543-553. PubMed ID: 37117135
[TBL] [Abstract][Full Text] [Related]
18. Implication of the Gut Microbiome and Microbial-Derived Metabolites in Immune-Related Adverse Events: Emergence of Novel Biomarkers for Cancer Immunotherapy.
Dora D; Bokhari SMZ; Aloss K; Takacs P; Desnoix JZ; Szklenárik G; Hurley PD; Lohinai Z
Int J Mol Sci; 2023 Feb; 24(3):. PubMed ID: 36769093
[TBL] [Abstract][Full Text] [Related]
19. Immune Checkpoint Inhibitors and Cardiac Toxicity in Patients Treated for Non-Small Lung Cancer: A Review.
Sławiński G; Wrona A; Dąbrowska-Kugacka A; Raczak G; Lewicka E
Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 33003425
[TBL] [Abstract][Full Text] [Related]
20. Use of glucocorticoids in the management of immunotherapy-related adverse effects.
Wang H; Zhou J; Guo X; Li Y; Duan L; Si X; Zhang L
Thorac Cancer; 2020 Oct; 11(10):3047-3052. PubMed ID: 32893490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
